Topical delivery of topical vismodegib in basal cell carcinomas
The aim was to investigate vismodegib concentration and tumor response to a topical vismodegib nanoemulsion. Basal cell carcinomas were exposed to ablative fractional laser and incubated with vismodegib emulsion. Subsequently vismodegib concentration in tumor tissue and tumor markers were established. Treatment safety was monitored as blood vismodegib levels and local skin responses.
Researcher
Katrine Togsverd-Bo, MD, Ph.D. DMSC
Project supervisors
Merete Haedersdal, Professor, MD, Ph.D. DMSC
Uffe Hoegh Olesen, senior researcher, Ph.D.
Project period
Year: 2019-2021
Project collaborators
Professor Thomas Andresen, senior researcher Gael Veiga, Danish Technical University.
Anni Linnet Nielsen, consultant oncologist, Herlev Gentofte Hospital.
Maria Høyer Hansen, LEO Pharma, Ballerup, Denmark
Financing
Capital Region Research Foundation
Selected publications
Olesen UH, Clergeaud G, Hendel KK, Yeung K, Lerche CM, Andresen TL, Haedersdal M. Enhanced and Sustained Cutaneous Delivery of Vismodegib by Ablative Fractional Laser and Microemulsion Formulation. J Invest Dermatol. 2020 Oct;140(10):2051-2059.
Olesen UH, Clergeaud G, Lerche CM, Andresen TL, Haedersdal M. Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro. Lasers Surg Med. 2019 Jan;51(1):79-87.
Olesen UH, Mogensen M, Haedersdal M. Vehicle type affects filling of fractional laser-ablated channels imaged by optical coherence tomography. Lasers Med Sci. 2017;32(3):679-684.
Olesen UH, Bojesen S, Gehl J, Haedersdal M. Anticancer drugs and the regulation of Hedgehog genes GLI1 and PTCH1, a comparative study in nonmelanoma skin cancer cell lines. Anticancer Drugs. 2017 Nov;28(10):1106-1117.